Perspectives in clinical immunology;Immunologia: Il futuro prossimo

Recenti Progressi in Medicina

Volumn 97, Issue 12, 2006, Pages 787-796

  Rolla, Giovanni ^a,b   Ferrero, Nicoletta ^a   Bergia, Roberta ^a   Guida, Giuseppe ^a  

^a Sezione di Chirurgia Generale   (Italy)

^b MAURIZIANO HOSPITAL   (Italy)

Author keywords

Abatacept; Basiliximab; Biological agents; Daclizumab; Immunosoppressive drugs; Leflunomide; Rituximab; Sirolimus

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; ABATACEPT; ADALIMUMAB; ALEFACEPT; ALEMTUZUMAB; ATLIZUMAB; BASILIXIMAB; BELIMUMAB; CLENOLIXIMAB; CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE; DACLIZUMAB; EFALIZUMAB; EPRATUZUMAB; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 2; KELIXIMAB; LEFLUNOMIDE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITUXIMAB; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ALLOTRANSPLANTATION; ANTIBODY PRODUCTION; AUTOIMMUNE DISEASE; GENETIC ENGINEERING; GRAFT REJECTION; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; DRUG THERAPY, COMBINATION; FORECASTING; GRAFT REJECTION; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; RECEPTORS, INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-2; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845931346     PISSN: 00341193     EISSN: 00341193     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747-55.
2. Curran MP, Perry CM. Tacrolimus in patients with rheumatoid arthritis. Drugs 2005; 65: 993-1001.
3. Appel GB, Radhakrishnan J, Ginzler EM. Use of mycophenolate mofetil in autoimmune and renal diseases. Transplantation 2005; 80: S265-71.
4. Kaltwasser JP, Behrens F. Leflunomide: long term clinical experience and new uses. Expert Opin Pharmacother 2005; 6: 787-801.
5. Genovese M.C., et al. Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition. N Engl J Med 2005; 353: 1114-23.
6. Quezada SA. Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis. Arthritis Rheum 2003; 48: 2541-54.
7. Bourneaud C, et al. Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 2000; 13: 829-840.
8. Sharma A, et al. Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4. J Pharmacol Exp Ther 2000; 293: 33-41.
9. Kuhrober A, et al. Vaccination with T cell receptor peptides primes anti-receptor cytotoxic T lymphocytes (CTL) and anergizes T cell specifically recognized by these CTL. Eur J Immunol 1994; 24: 1172-80.
10. Bourdette DN, et al. Immunity to TCR peptides in multiple sclerosis. Successful immunization of patients with syntethic V beta 5.2 and V beta 6.1 CDR2 peptides. J Immunol 1994; 152: 2510-19.
11. Furie R, et al. Safety, pharmacokynetic and pharmacodynamic results of a phase 1 single and double-excalation study of LYNPHOSTAT-B (human monoclonal antibody to BLyS) in SLE patients. Arthritis Rheum 2003; 48 Suppl: S377[abstract].
12. McKay J, et al. Belimumab (BmAb) a fully human monoclonal antibody to B-lynphocitic, stimulator (BLyS), combined with standard of care teraphy reduced the signs and symptoms of RA in a heterogeneous subjects populations. Arthritis Rheum 2005; 52 Suppl: S710-S711 [abstract].
13. Dorner T, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006; 8: R74.
14. Davis JC, et al. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 95-101.
15. Lenert P, et al. Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases? Clin Exp Immunol 2005; 140: 1-10.
16. Edwards JC, et al. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006; 6: 394-403.
17. Looney RJ, et al. New therapies for systemic lupus erythematosus: cellular targets. Rheum Dis Clin North Am 2006; 32: 201-15.
18. Zaja F, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101: 3827-34. Epub 2003 Jan 30.
19. Looney RJ. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis. Rheumatology (Oxford). 2005; 44 suppl 2: ii13-ii17.
20. Luster AD, et al. Immune cell migration in inflammation: present and future therapeutics targets. Nat Immunol 2005; 6: 1182-1189.
21. Charo IF, et al. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006; 354: 610-21.
22. Utrich HVA, et al. α4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003; 348: 68-72.
23. Schon MP, et al. Psoriasis. NEJM 2005; 352: 1899.
24. Targan SR. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
25. Maini RN. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004; 50: 1051-65.
26. Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990; 33: 305-15.
27. Kolls JK. Anti-interleukin-12 antibody for active Crohn's disease. NEJM 2005; 352: 627-8.
28. Genovese MC. Biologic therapies in clinical development for the treatment of rheumatoid arthritis. J Clin Rheumatol 2005; 11(3 suppl): S45-54.
29. Krueger, JG, et al. Successful in vivo blockade of CD25 (high-infinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 2000; 43: 448-58.
30. Nussenblatt RB. Bench to bedside: new approaches to the immunotherapy of uveitic disease. Int Rev Immunol 2002; 21: 273-89.
31. Liu K et al. Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med 2002; 196: 1627-38.
32. Morita Y, et al. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest 2001; 107: 1275-84.
33. Gauzzi MC, et al. Suppressive effect of 1α25-dihydroxyvitamin D3 on type I IFN-mediated monocyte differentiation into dendritic cells: impairment of functional activities and chemotaxis. J Immunol 2005; 174: 270-6.
34. Napolitani G, et al. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type1-polarizing program in dendritic cells. Nat Immunol 2005; 6: 769-76.